Apogee Therapeutics, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net
Apogee Therapeutics, Inc. (APGE) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net of $10.20 million for the 11-month period ending 2022-12-31, per its 10-K filed 2024-03-05.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet · last filed 2024-03-05
- 2022-12-31: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 11 month $10.20M.
- 2022-09-30: Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 8 month -$600.00K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 8 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 11 month |
|---|---|---|
| 2022-12-31 | $10.20M 10-K · filed 2024-03-05 | |
| 2022-09-30 | -$600.00K 10-Q · filed 2023-11-13 |